DOCSLIB.ORG

WO 2017/172603 Al 5 October 2017 (05.10.2017) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2017/172603 Al 5 October 2017 (05.10.2017) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/172603 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: c/o Tioga Research, Inc., 6330 Nancy Ridge Drive, Suite A61K 31/197 (2006.01) A61K 31/00 (2006.01) 102, San Diego, California 92121 (US). A61K 9/00 (2006.01) A61K 31/195 (2006.01) (74) Agents: TANNER, Lorna L. et al; SHEPPARD MUL- A61K 9/06 (2006.01) LIN RICHTER & HAMPTON LLP, 379 Lytton Avenue, (21) International Application Number: Palo Alto, California 94301-1479 (US). PCT/US20 17/024281 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 27 March 2017 (27.03.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/390,369 28 March 2016 (28.03.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: TIOGA RESEARCH, INC. [US/US]; 6330 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, Nancy Ridge Drive, Suite 102, San Diego, California TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 9212 1 (US). ZA, ZM, ZW. (72) Inventors: KISAK, Edward T.; c/o Tioga Research, Inc., (84) Designated States (unless otherwise indicated, for every 6330 Nancy Ridge Drive, Suite 102, San Diego, California kind of regional protection available): ARIPO (BW, GH, 9212 1 (US). NEWSAM, John M.; c/o Tioga Research, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Inc., 6330 Nancy Ridge Drive, Suite 102, San Diego, Cali TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, fornia 92121 (US). BUYUKTIMKIN, Servet; c/o Tioga TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Research, Inc., 6330 Nancy Ridge Drive, Suite 102, San DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Diego, California 92121 (US). BUYUKTIMKIN, Nadir; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on nextpage] (54) Title: TOPICAL FORMULATION (57) Abstract: Provided herein are top ical formulations. The topical formula tion may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combina tions of DMSO with a keto acid such as levulinic acid and/or with a fatty al I cohol such as oleyl alcohol are excel ■ lent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin. 1 1 w o 2017/172603 Illlll II Hill lllll Hill llll III III Hill lllll Hill lllll Hill llll limn i i llll SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, KM, ML, MR, NE, SN, TD, TG). — with international search report (Art. 21(3)) Declarations under Rule 4.17: — before the expiration of the time limit for amending the — as to the applicant's entitlement to claim the priority of claims and to be republished in the event of receipt of the earlier application (Rule 4.17(Hi)) amendments (Rule 48.2(h)) TOPICAL FORMULATION CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The application claims the benefit under 35 U.S.C. § 119(e) of United States Provisional Application 62/390,369, filed March 28, 2016, which is hereby incorporated by reference in its entirety. FIELD [0002] The present disclosure relates to a topical formulation of a pharmaceutical agent comprising multiplexed molecular penetration enhancers. BACKGROUND [0003] The administration of a drug through the skin for systemic distribution, that is transdermally, can provide compelling advantages relative to other modes of administration. Transdermal administration circumvents potential complications in the gastrointestinal ("GI") tract, avoids first-pass metabolism in the liver, can allow delivery of an active ingredient with a relatively short biological half-life or a narrow therapeutic window, facilitates uniform plasma dosing of the active ingredient, and, as above, is broadly preferred from a user compliance perspective. [0004] In spite of the advantages, transdermal administration is limited to only a small number of drugs. For example, a transdermal patch format is currently limited to some thirty drugs (including scopolamine, fentanyl, estradiol, nitroglycerin, nicotine, testosterone, selegiline and methyl phenidate). The reason for the paucity of transdermal products to treat serious pain conditions is that the skin presents a formidable barrier. [0005] Structurally, the skin consists of two principle layers: (i) the epidermis, the outermost layer, which varies in thickness from 0.05 mm on the eyelids to 1.5 mm on the palms and soles of the feet but which typically averages 80 µπ , and (ii) the 'dermis,' the inner region, ranges in thickness from 0.4 to 4mm, with a typical average of 2mm. The outermost layer of the epidermis (the 'stratum corneum') comprises corneocytes (flattened dead cells which are filled with keratin), interconnected by corneodesmosomes and surrounded by lipids which form lamellar phases. The highly impermeable nature of skin is due primarily to the stratum corneum. The viable epidermis underlying the stratum corneum is akin to other living tissue. The dermis provides the skin's structural strength as well as the nerve and vascular networks that support the epidermis. [0006] Various factors can affect the skin absorption rates and penetration depths of a drug molecule applied in a formulation to the skin, including the nature of the active ingredient, the nature of the vehicle, the pH, and the relative solubility of the active in the vehicle versus the skin. More specifically, drug attributes such as solubility, size and charge, melting point as well as vehicle attributes such as the drug solubility and dissolution rate, ability to alter the membrane permeability, spreadability and adhesion can each have significant effects on permeability. [0007] Delivering an active agent into or through the skin in sufficient concentrations usually requires some means for reducing the stratum corneum's hindrance to ingress of the active agent. A number of physical methods for lowering the stratum corneum's barrier properties have been developed including electrically assisted techniques such as iontophoresis or electroporation, ultrasound, heat, puncturing the stratum corneum with microneedle arrays, or ablation. Even for a single, non-repeated application such physical methods have limitations, leading to very restricted use by patients in practice. SUMMARY [0008] Some embodiments provide for a topical formulation comprising multiplexed molecular penetration enhancers for topical or transdermal administration of a zwitterionic pharmaceutical agent. In some embodiments, the present disclosure relates to a topical formulation comprising multiplexed molecular penetration enhancers for topical or transdermal administration of a gabapentinoid. In some embodiments, the present disclosure relates to a topical formulation comprising multiplexed molecular penetration enhancers for topical or transdermal administration of pregabalin. [0009] In another of its aspects, the present disclosure provides a topical formulation for use in topical or transdermal administration of a substance comprising: (i) at least one active agent, (ii) DMSO, (iii) a keto acid, and (iv) a fatty acid ester. [0010] In another of its aspects, the present disclosure provides a topical formulation comprising: (i) at least one active agent, (ii) water, (iii) dimethyl sulfoxide ("DMSO"), (iv) a keto acid, and (v) an ester of a fatty alcohol and an a-hydroxy acid, an ester of a fatty acid and an alcohol, or a mixture thereof. [0011] In another of its aspects, the present disclosure provides a topical formulation comprising: (i) at least one active agent, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) a fatty alcohol. [0012] In another of its aspects, the present disclosure provides a topical formulation for use in topical or transdermal administration of a substance comprising: (i) at least one active agent, (ii) DMSO, (iii) levulinic acid, and (iv) lauryl lactate. [0013] In another of its aspects, the present disclosure provides a topical formulation for use in topical or transdermal administration of a substance comprising: (i) at least one active agent, (ii) DMSO, (iii) a keto acid, (iv) a fatty acid ester, and (v) a polyalkylene glycol alkyl ether. [0014] In another of its aspects, the present disclosure provides a topical formulation for use in topical or transdermal administration of a substance comprising: (i) at least one active agent, (ii) DMSO, (iii) levulinic acid, (iv) lauryl lactate, and (v) a polyethylene glycol alkyl ether. [0015] In another of its aspects, the present disclosure provides a topical formulation for use in topical or transdermal administration of a substance comprising: (i) at least one active agent, (ii) DMSO, (iii) levulinic acid, (iv) lauryl lactate, and (v) dimethyl isosorbide. [0016] In another of its aspects, the present disclosure provides a topical formulation for use in topical or transdermal administration of a substance comprising: (i) at least one active agent, (ii) DMSO, (iii) a fatty alcohol or a fatty acid ester, and (iv) a polyalkylene glycol alkyl ether.
Load more

Recommended publications
  • Neurontin (Gabapentin)
    Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Gabapentin Clinical Criteria Information Included in this Document Neurontin (gabapentin) • Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria • Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules • Logic diagram: a visual depiction of the clinical criteria logic • Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable • References: clinical publications and sources relevant to this clinical criteria Note: Click the hyperlink to navigate directly to that section. Gralise (gabapentin Extended Release) • Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria • Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules • Logic diagram: a visual depiction of the clinical criteria logic • Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable • References: clinical publications and sources relevant to this clinical criteria Note: Click the hyperlink to navigate directly to that section. March 29, 2019 Copyright © 2019 Health Information Designs, LLC 1 Horizant
    [Show full text]
  • Métrologie De La Douleur Animale Sur Modèles Expérimentaux : Développement Et Validation De Biomarqueurs Neuroprotéomiques
    Université de Montréal Métrologie de la douleur animale sur modèles expérimentaux : développement et validation de biomarqueurs neuroprotéomiques. par Colombe Otis Département de biomédecine vétérinaire Faculté de médecine vétérinaire Thèse présentée à la Faculté de médecine vétérinaire en vue de l’obtention du grade de philosophiæ doctor (Ph. D.) en sciences vétérinaires option pharmacologie Août, 2017 © Colombe Otis, 2017 Résumé La douleur est un phénomène complexe et dynamique comprenant un processus primaire et sensoriel, la nociception, auquel se rajoutent des réactions de défense et d'alarme psychophysiologiques. Ceci conduit au développement d'une véritable mémoire de la douleur, individuelle et modulée (plasticité neuronale) par des expériences précédentes de douleur, incluant entre autres, des phénomènes de sensibilisation nociceptive. Pour bien comprendre les mécanismes de sensibilisation centrale, les modèles animaux mimant les pathologies humaines sont d’une importance primordi ale. Or, pour ce faire, nous avons proposé une série d'approches expérimentales translationnelles par le développement de modèles expérimentaux de douleur bovine, canine et murine afin de caractériser les atteintes du protéome spinal en fonction du niveau de douleur perçu par l'animal et d’identifier le (les) marqueur (s) potentiellement modulé (s) par la sensibilisation nociceptive. À l’aide de la neuroprotéomique, nous avons identifié sur un modèle bovin de douleur viscérale, la protéine transthyrétine (TTR) comme étant sous-exprimée dans le protéome spinal en présence de douleur et ce, vérifié également dans le modèle canin de douleur chronique liée à l’arthrose chirurgicale. Ces résultats suggèrent la possibilité d’entrevoir la TTR comme un biomarqueur potentiel de la douleur chronique. Notre découverte de la relation entre les niveaux spinaux de TTR par neuroprotéomique et l’ hypersensibilité à la douleur dans les modèles bovin et canin soutiennent l’implication de composantes inflammatoires nociceptives et immunitaires.
    [Show full text]
  • Phenibut Overdose in Combination with Fasoracetam: Emerging Drugs of Abuse
    Open Access Journal of Clinical Intensive Care and Medicine Case Report Phenibut Overdose in Combination ISSN with Fasoracetam: Emerging Drugs 2639-6653 of Abuse Cristian Merchan1*, Ryan Morgan1, John Papadopoulos1,2 and David Fridman2 1Department of Pharmacy, New York University Langone Medical Center, New York, USA 2New York University School of Medicine, New York, USA *Address for Correspondence: Dr. Cristian INTRODUCTION D Merchan, Pharm.D, BCCCP, Critical Care Pharmacotherapist, Department of Pharmacy, The widespread availability of non-traditional dietary supplements and New York University Langone Medical Center, pharmacologically active substances via the Internet continues to introduce New York, USA, Tel: 516-263-1671; Email: [email protected] mechanisms for inadvertent toxidromes not commonly seen. Consumers are virtually unrestricted in their ability to acquire products purporting augmentation of normal Submitted: 25 October 2016 Approved: 15 December 2016 physiology for the purposes of enhancement, recreation, and/or potential abuse. The Published: 17 December 2016 safety proiles at standard or toxic doses remain largely unknown for many agents that Copyright: 2016 Merchan et al. This is an can be purchased electronically. We report a case of mixed toxicity related to phenibut open access article distributed under the and fosaracetam, both of which are readily available for consumer purchase from Creative Commons Attribution License, which online retailers. Written and verbal consent was obtained for this case presentation. permits unrestricted use, distribution, and reproduction in any medium, provided the CASE REPORT original work is properly cited. Keywords: Nootropic; GABA agonist; Drug of A 27-year-old male with a past medical history of anxiety was discovered abuse; Dietary supplement; Alternative medicine unresponsive on the sidewalk.
    [Show full text]
  • Preventive Report Appendix
    Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents.
    [Show full text]
  • Conjugation of Tryptamine to Biologically Active Carboxylic Acids in Order to Create Prodrugs
    ISSN 2380-5064 | The Arsenal is published by the Augusta University Libraries | http://guides.augusta.edu/arsenal Volume 4, Issue 1 (2021) Special Edition Issue CONJUGATION OF TRYPTAMINE TO BIOLOGICALLY ACTIVE CARBOXYLIC ACIDS IN ORDER TO CREATE PRODRUGS Colin Miller, Jr. and Iryna O. Lebedyeva Citation Miller, C., Jr., & Lebedyeva, I. O. (2021). Conjugation of tryptamine to biologically active carboxylic acids in order to create prodrugs. The Arsenal: The Undergraduate Research Journal of Augusta University, 4(1), 26. http://doi.org/10.21633/issn.2380.5064/s.2021.04.01.26 © Miller, Jr. and Lebedyeva 2021. This open access article is distributed under a Creative Commons Attribution NonCommercial-NoDerivs 2.0 Generic License (https://creativecommons.org/licenses/by-nc-nd/2.0/). Conjugation of Tryptamine to Biologically Active Carboxylic Acids in Order to Create Prodrugs Presenter(s): Colin Miller, Jr. Author(s): Colin Miller Jr. and Iryna O. Lebedyeva Faculty Sponsor(s): Iryna O. Lebedyeva, PhD Affiliation(s): Department of Chemistry and Physics (Augusta Univ.) ABSTRACT A number of blood and brain barrier penetrating neurotransmitters contain polar functional groups. Gamma-aminobutyric acid (GABA) is an amino acid, which is one of the primary inhibitory neurotransmitter in the brain and a major inhibitory neurotransmitter in the spinal cord. Antiepileptic medications such as Gabapentin, Phenibut, and Pregabalin have been developed to structurally represent GABA. These drugs are usually prescribed for the treatment of neuropathic pain. Since these drugs contain a polar carboxylic acid group, it affects their ability to penetrate the blood and brain barrier. To address the low bioavailability and tendency for intramolecular cyclization of Gabapentin, its less polar prodrug Gabapentin Enacarbil has been approved in 2011.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,283,487 B2 Ben Moha-Lerman Et Al
    USOO8283487B2 (12) United States Patent (10) Patent No.: US 8,283,487 B2 Ben Moha-Lerman et al. (45) Date of Patent: Oct. 9, 2012 (54) PROCESSES FOR THE PREPARATION AND 2003/0176398 A1 9/2003 Gallop et al. PURIFICATION OF GABAPENTIN 2004/0077553 A1* 4/2004 Gallop et al. ................... 514, 19 2005/O154057 A1 7/2005 Estrada et al. ENACARBL 2007/0049627 A1 3, 2007 Tran (75) Inventors: Elena Ben Moha-Lerman, Kiryat Ono FOREIGN PATENT DOCUMENTS (IL); Tamar Nidam, Yehud (IL); Meital WO WO O2/10O347 12/2002 Cohen, Petach-Tikva (IL); Sharon WO WO 2005/0377.84 4/2005 Avhar-Maydan, Givataym (IL); Anna Balanov, Rehovot (IL) OTHER PUBLICATIONS X. Yuan et al. “In Situ Preparation of Zinc Salts of Unsaturated (73) Assignee: Teva Pharmaceutical Industries Ltd., Carboxylic Acids to Reinforce NBR' J. Applied Polymer Science, Petach-Tikva (IL) vol. 77, p. 2740-2748 (2000). - r J. Alexander et al. “(Acyloxy)alkyl Carbamates as Novel Biorevers (*) Notice: Subject to any disclaimer, the term of this ible Prodrugs for Amines: Increased Permeation through Biological patent is extended or adjusted under 35 Membranes”.J. Med. Chem. 1988, 31, pp. 318-322. U.S.C. 154(b) by 249 days. S.M. Rahmathullah et al. “Prodrugs for Amidines: Synthesis and Anti-Pneumocystis carinii Activity of Carbamates of 2.5-Bis(4- (21) Appl. No.: 12/626,682 amidinophenyl)furan” J. Med. Chem. 1999, 42, pp. 3994-4000. (22) Filed: Nov. 26, 2009 * cited by examiner (65) Prior Publication Data Primary Examiner — Joseph K. McKane US 2010/O160665 A1 Jun. 24, 2010 Assistant Examiner — Alicia L Otton (74) Attorney, Agent, or Firm — Arent Fox LLP Related U.S.
    [Show full text]
  • More Treatments on Deck for Alcohol Use Disorder
    News & Analysis Medical News & Perspectives More Treatments on Deck for Alcohol Use Disorder Jeff Lyon hirteen years have passed since the Raye Z. Litten, PhD, acting director of the ment for AUD were actually prescribed an US Food and Drug Administration NIAAA’s Division of Medications Develop- AUD medication. T (FDA) last approved a new medica- ment and principal investigator of the trial, It is a complicated problem, says John tion to help the nation’s millions of people says the agency is “excited.” Rotrosen, MD, a psychiatrist and addiction withalcoholusedisorder(AUD)stopormod- Nevertheless, the science of alcohol ad- specialist at New York University School of erate their drinking. diction has seen its share of medicines that Medicine. “To a large extent primary care Only 3 such formulations exist, and 1, failed to live up to their early promise dur- physicians don’t screen for alcoholism,” he disulfiram, dates to the Prohibition era. ing full-scale testing. So Litten said the said. “When they do, they may note it, but Known commercially as Antabuse and agency isn’t putting all its eggs in one bas- don’t really do anything about it.” introduced in 1923, it makes people memo- ket. “You need as many weapons as pos- As far as the failure to prescribe exist- rably ill if they ingest alcohol, but it doesn’t sible to treat a complex disease like alcohol ing medications for AUD, Rotrosen blames stop the cravings. The other 2, naltrexone use disorder,” he said. a lack of knowledge. “A lot of doctors in and acamprosate, approved in 1994 and But therein lies a second difficulty.
    [Show full text]
  • Gabapentin Abuse Gabapentin (Neurontin®) Is Indicated for the Treatment of Epilepsy and Neuro- Pathic Pain, Including Post-Herpetic Neuralgia
    November 2018 Poison Center Hotline: 1-800-222-1222 The Maryland Poison Center’s Monthly Update: News, Advances, Information Gabapentin Abuse Gabapentin (Neurontin®) is indicated for the treatment of epilepsy and neuro- pathic pain, including post-herpetic neuralgia. Gabapentin is often prescribed off -label for a variety of conditions including insomnia, anxiety, bipolar disorder, migraines, drug and alcohol addiction, and others. Off-label use exceeds use for FDA approved indications. Termed a gabapentinoid, it is an analog of γ- aminobutyric acid (GABA) that increases GABA but does not bind to GABA re- ceptors. It has a selective inhibitory effect on voltage-gated calcium channels containing the α2δ1 subunit. Its exact mechanism for epilepsy and pain is un- clear. Gabapentin is not a controlled substance as it was believed that gabapentin had no abuse potential when approved by the FDA in 1993. Overall, if used at thera- Did you know? peutic doses by patients without a substance abuse/misuse history, the risk of misuse is probably lower than that of other drugs such as benzodiazepines. There are reports of abuse of However, reports are increasing of gabapentin misuse and abuse. Motivations pregabalin (Lyrica ®), another for misuse include recreational use, mood and/or anxiety control, potentiating gabapentinoid used for the effects of drug abuse treatment, pain management, reducing cravings for neuropathic pain, post-herpetic other drugs, managing withdrawal from other drugs, substituting for other pain and fibromyalgia. drugs, and gabapentin addiction (Addiction 2016;11:1160-74). The risk of misuse Approved by the FDA in 2004, increases in people with a history of recreational drug abuse who take gabapen- pregabalin is Schedule V.
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
    University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines
    [Show full text]
  • 4Th Quarter 2020 DEA
    QUARTERLY REPORT 4th Quarter – 2020 U.S. Department of Justice Drug Enforcement Administration Diversion Control Division Drug and Chemical Evaluation Section Drug Enforcement Administration – Toxicology Testing Program Contents Introduction ............................................................ 3 Summary ................................................................. 4 NPS Discovered via DEA TOX ................................. 5 New Psychoactive Substances ............................... 6 Traditional Illicit Drugs ........................................... 8 Prescription and Over the Counter Drugs ............. 9 Contact Information ............................................. 10 2 | Page 4th Quarter Report – 2020 Drug Enforcement Administration – Toxicology Testing Program Introduction The Drug Enforcement Administration’s Toxicology Testing Program (DEA TOX) began in May 2019 as a surveillance program aimed at detecting new psychoactive substances within the United States. In response to the ongoing synthetic drug epidemic, the Drug Enforcement Administration (DEA) awarded a contract with the University of California at San Francisco (UCSF) to analyze biological samples generated from overdose victims of synthetic drugs. In many cases, it can be difficult to ascertain the specific substance responsible for the overdose. The goal of DEA TOX is to connect symptom causation to the abuse of newly emerging synthetic drugs (e.g. synthetic cannabinoids, synthetic cathinones, fentanyl-related substances, other hallucinogens, etc.).
    [Show full text]
  • Gabapentinoids: Pharmacokinetics, Pharmacodynamics and Considerations for Clinical Practice
    912496BJP British Journal of PainChincholkar Special Issue Article British Journal of Pain 1 –11 Gabapentinoids: pharmacokinetics, © The British Pain Society 2020 Article reuse guidelines: sagepub.com/journals-permissions pharmacodynamics and considerations DOI:https://doi.org/10.1177/2049463720912496 10.1177/2049463720912496 for clinical practice journals.sagepub.com/home/bjp Mahindra Chincholkar Abstract The gabapentinoids are often recommended as first-line treatments for the management of neuropathic pain. The differing pharmacodynamic and pharmacokinetic profiles can have implications for clinical practice. This article has summarised these key differences. In addition to their use in managing neuropathic pain, gabapentinoids are increasingly being used for off-label conditions despite the lack of evidence. Prescription rates for off-label conditions have overtaken that for on-label use. Similarly, the use of gabapentinoids in the perioperative period is now embedded in clinical practice despite conflicting evidence. This article summarises the risks associated with this increasing use. There is increasing evidence of the potential to cause harm in vulnerable populations such as the elderly and increasing prevalence of abuse. The risk of respiratory depression in combination with opioids is of particular concern in the context of the current opioid crisis. This article describes the practical considerations involved that might help guide appropriate prescribing practices. Keywords Gabapentin, pregabalin, pain management, adverse effects, pharmacology Introduction movement, sleep disorders, headaches, alcohol with- drawal syndrome, chronic back pain, fibromyalgia, vis- The gabapentinoid drugs gabapentin and pregabalin ceral pain and acute postoperative pain.4,5 The rate of are antiepileptic drugs that are considered as first-line new prescriptions is increasing and tripled in England 1 treatments for the management of neuropathic pain.
    [Show full text]